Recent attention has been paid to anticancer agents and other therapies that induce oxidative stress by increasing reactive oxygen species (ROS) or by inhibiting antioxidative processes. However, the roles of ROS in physiological and pathological conditions are complex, and mechanisms leading to their interactions with treatment modalities continue to emerge. Therefore, additional insights into interactions of oxidative stress with biological processes and the clinical implications of these interactions are critical for the improvement of strategies to treat many diseases.
Oxidative stress is an important factor in the occurrence and development of various human diseases, including cancers. Oxidative stress can be exacerbated by ROS that are produced in the mitochondria, peroxisomes and the endoplasmic reticulum. ROS are also continuously generated by enzymatic reactions involving cyclooxygenases, xanthine oxidases, lipoxygenases, and NADPH oxidases (NOXs), as well as through the iron-catalyzed Fenton reaction, all of which can be modulated by drugs or other therapies. ROS are also generated upon exposure to physical agents, including ultraviolet radiation and heat. Notably, some cancer therapies, including chemo- and radio-therapies, rely on ROS production and oxidative stress to realize their full potential.
In this Research Topic, we aim to provide an overview of recent progress in oxidative stress and related factors, especially with regard to impacts of drug-induced oxidative stress on physiological and pathological processes. Analysis of the outcomes of drug-induced oxidative stress will permit the development of novel ways to limit its harmful effects and to augment its beneficial outcomes. Novel strategies to allow clinicians to utilize potential applications of ROS-related therapies will be an area of focus.
We welcome submissions of Reviews, Mini-Reviews and Original Research Articles covering, but not limited to, the following topics:
• Strategies to maximize ROS production and oxidative stress in the treatment of malignancies
• Oxidative responses to inflammation associated with therapies
• The role of NOXs in oxidative stress-related diseases
• Damage to other organs due to drug-induced oxidative stress
• Cardiovascular injury resulting from oxidative stress
Recent attention has been paid to anticancer agents and other therapies that induce oxidative stress by increasing reactive oxygen species (ROS) or by inhibiting antioxidative processes. However, the roles of ROS in physiological and pathological conditions are complex, and mechanisms leading to their interactions with treatment modalities continue to emerge. Therefore, additional insights into interactions of oxidative stress with biological processes and the clinical implications of these interactions are critical for the improvement of strategies to treat many diseases.
Oxidative stress is an important factor in the occurrence and development of various human diseases, including cancers. Oxidative stress can be exacerbated by ROS that are produced in the mitochondria, peroxisomes and the endoplasmic reticulum. ROS are also continuously generated by enzymatic reactions involving cyclooxygenases, xanthine oxidases, lipoxygenases, and NADPH oxidases (NOXs), as well as through the iron-catalyzed Fenton reaction, all of which can be modulated by drugs or other therapies. ROS are also generated upon exposure to physical agents, including ultraviolet radiation and heat. Notably, some cancer therapies, including chemo- and radio-therapies, rely on ROS production and oxidative stress to realize their full potential.
In this Research Topic, we aim to provide an overview of recent progress in oxidative stress and related factors, especially with regard to impacts of drug-induced oxidative stress on physiological and pathological processes. Analysis of the outcomes of drug-induced oxidative stress will permit the development of novel ways to limit its harmful effects and to augment its beneficial outcomes. Novel strategies to allow clinicians to utilize potential applications of ROS-related therapies will be an area of focus.
We welcome submissions of Reviews, Mini-Reviews and Original Research Articles covering, but not limited to, the following topics:
• Strategies to maximize ROS production and oxidative stress in the treatment of malignancies
• Oxidative responses to inflammation associated with therapies
• The role of NOXs in oxidative stress-related diseases
• Damage to other organs due to drug-induced oxidative stress
• Cardiovascular injury resulting from oxidative stress